Media
Pharma Biz
Imugene announces phase 1b trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma
Applied Clinical Trials
Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pharma in Focus
Blood cancer trial astounds again
Proactive Investors
Imugene secures $22.5 million placement and launches $15 million SPP to fund azer-cel trial
Money News Podcast
Leslie Chong, Imugene CEO
BioWorld
Imugene’s allogeneic CD19 CAR T sees 75% response rate
Biotech Dispatch
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial
Proactive Investors
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Proactive Investors
Imugene’s azer-cel shows strong results in Phase 1b trial for DLBCL, set for FDA meeting
Proactive Investors
Imugene doses first patient in Australia for PD1-Vaxx Neo-POLEM Phase II trial
BiotechDispatch
Imugene announces US patent allowance for onCARlytics
Proactive Investors